Anlotinib Is Active for the Patients Failed From the Prior Antiangiogenic Therapy: Anti-angiogenic Therapy Might Be Cross-line Used

Jiaojiao Suo  
Sichuan University West China Hospital

Yu Sun  
Sichuan University West China Hospital

Yan Fu  
Sichuan University West China Hospital

Weigang Xiu  
Sichuan University West China Hospital

Xuanwei Zhang  
Sichuan University West China Hospital

Yan Wang  
Sichuan University West China Second University Hospital

Jiang Zhu (✉ zhuijiang@wchscu.cn)  
Department of Thoracic Oncology  https://orcid.org/0000-0002-5496-8450

Research Article

Keywords: Anlotinib, lung cancer, antiangiogenic, efficacy

DOI: https://doi.org/10.21203/rs.3.rs-682548/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Objective** The purpose of this study was to initially investigate whether previous antiangiogenic therapy (bevacizumab and endostar) affect the efficacy of anlotinib in patients with lung cancer (LC).

**Methods** We retrospectively collected the clinical data of LC patients treated with anlotinib. They were divided into two groups, namely group A (anlotinib after failure of previous antiangiogenic drugs and group B (no prior use of antiangiogenic drugs). Use propensity score matching (PSM) to control the confounding factors between the groups.

**Results** A total of 160 patients were included in the analysis. The median OS in group A and group B was 11.8 months vs. 16.1 months (P=0.120), and the median PFS was 3.1 months, 4.7 months, respectively (P=0.009). The ORR of the two groups was 9.6% vs. 10.4% (P=0.874), and the DCR was 71.1 % vs. 80.5% (P=0.165).

After PSM (n=46), baseline characteristics were equitably comparable between the two groups. It was found that the median OS of the two groups was 14.6 months vs. 16.2 months (P=0.320), and the median PFS was 3.5 months vs. 4.5 months (P=0.040). The ORR of the two groups were 13.0%, 10.9% (P=0.748), and the DCR were 78.3%, 82.6% (P=0.599), respectively. These results provided further evidence that although PFS of group A was relatively shorter than that of group B, it may not affect patients’ OS.

**Conclusions** Previous antiangiogenesis treatments may affect the PFS of patients who receive anlotinib later, but it might not affect the patient’s ORR and OS.

Background

In recent years, malignant tumors have become one of the major global public health problems, among which lung cancer (LC) is one of the most common malignant tumors[1]. In 2020, the newly diagnosed patients with lung cancer accounted for 11.4% of all malignant tumors, and 1.8 million people died of lung cancer, which posed a great burden to individuals, families and society[2].

According to the NCCN guidelines[3], for advanced non-small cell lung cancer (NSCLC) without driver gene mutations, platinum-containing chemotherapy with or without antiangiogenesis therapy (bevacizumab or endostar) or immune checkpoint inhibitors significantly prolonged the patients'overall survival (OS) and progression-free survival (PFS) and was the standard first-line treatment [4-6].Docetaxel, pemetrexed and immune checkpoint blockers were considered second-line therapies [7-9].For small cell lung cancer (SCLC), etoposide + platinum combined with atezolizumab was recommended as the first-line treatment [10], while irinotecan, docetaxel, paclitaxel, pembrolizumab and other drugs can be selected as the second-line treatment [11]. First- and second-line treatment have significantly improved the survival of LC patients. More LC patients are still in good physical condition after receiving the recommended standard treatment, they need safe and more effective third- and further-
line treatment. Anlotinib is an oral antiangiogenic tyrosine kinase inhibitor (TKI), studies have shown that anlotinib could significantly improve PFS and OS of patients with advanced LC in third- and further-line treatment, and had acceptable tolerance [12-15]. Anlotinib was approved for the treatment of patients with advanced LC who progressed after two-line therapy.

In addition to chemotherapy, radiotherapy, targeted therapy and immunotherapy, anti-angiogenesis therapy is one of the important anti-tumor methods for advanced lung cancer [16]. Bevacizumab was one of the first approved and most widely used macromolecular angiogenesis inhibitor. Bevacizumab targeted the tumor microenvironment and provided a significant survival benefit in combination with standard chemotherapy for patients with advanced LC (excluding squamous cell carcinoma) [17]. Subsequently, recombinant human endostatin endostar combined with chemotherapy also prolonged PFS and OS in NSCLC patients and was approved as first-line therapy [18]. Anlotinib simultaneously inhibits vascular endothelial growth factor receptor (VEGFR) 1-3, platelet-derived growth factor receptor (PDGFR)-α, fibroblast growth factor receptor (FGFR) 1-3, c-kit and c-met. It can competitively bind intracellular tyrosine kinase domain, inhibit the phosphorylation process of intracellular tyrosine kinase domain, block downstream ERK signaling pathway, and effectively inhibit tumor angiogenesis and tumor growth [19].

In advanced colorectal cancer, several studies have demonstrated that bevacizumab cross-line therapy provides a definite benefit in OS and PFS [20, 21]. Moreover, continued antiangiogenic therapy with regorafenib still benefited colorectal cancer patients after progression with bevacizumab [22, 23]. The possible mechanism was that regorafenib not only inhibited the VEGF pathway, but also inhibited other angiogenic bypasses. In lung cancer, it is not clear whether antiangiogenic drugs can be cross-line used to induce sustained vascular inhibition. A retrospective study of 118 patients with advanced NSCLC showed no benefit from continued second-line bevacizumab after progression of first-line treatment with bevacizumab or endostar [24]. After failure of single-target bevacizumab therapy, the effectiveness of switching to another small-molecule multi-target antiangiogenic agent deserves further investigation. Retrospective studies have shown that previous antiangiogenesis therapies (bevacizumab or endostar) may not affect the efficacy of retro-line anlotinib therapy, suggesting that there may be no cross-resistance between anlotinib and other antiangiogenesis agents [25-27]. Existing research sample size was small, so this study retrospectively analyzed the efficacy of anlotinib in patients with advanced LC, and preliminarily observed whether previous antiangiogenic drugs affected the efficacy of anlotinib.

Methods

Patients

We scanned the medical data of LC patients treated with anlotinib admitted to West China hospital from June 2018 to January 2021. One hundred and seventy-two patients were treated with anlotinib. Three cases were lost to follow-up, 2 cases were discontinued anlotinib several days, of which one was due to dizziness, the other was due to fatigue, hypertension, and proteinuria. And 7 cases could not be
performed efficacy evaluation (due to imaging inaccessibility), therefore excluded. A total of 160 patients were included in the analysis.

Groups

Group A: patients treated with anlotinib after failure of antiangiogenesis therapy (bevacizumab or endostar), were assigned to group A (83 cases).

Group B: patients treated with anlotinib without any previous antiangiogenic therapy, were assigned to group B (77 cases).

Therapeutic regimen

The initial dose of anlotinib was 12mg or 10mg orally once daily on day 1-14, every 3 weeks. Some patients were reduced to 10mg/ day or 8mg/ day due to intolerant adverse reactions. Anlotinib was continued until disease progression or the adverse reaction was not tolerated. The regimens for anlotinib include:(1) anlotinib monotherapy;(2) anlotinib combined with chemotherapy (no restriction on chemotherapy regimen); (3) anlotinib combined with immune checkpoint inhibitors (anti-PD-1 /L1 antibodies); (4) anlotinib combined with targeted agents (including epidermal growth factor receptor TKI and ALK/ROS inhibitors); (5) anlotinib combined with local radiotherapy (no limitation on radiotherapy site and dose).

Efficacy evaluation

Radiographic examinations were performed to evaluate the efficacy 2 cycles after initiation, and then every 2 cycles or periodically according to clinical conditions. Efficacy evaluation was performed by the researchers directly through Picture Archiving and Communication Systems (PACS) in the hospital according to Response Evaluation Criteria In Solid Tumour 1.1(RECIST 1.1), with reference to imaging reports and clinical practice. The best response evaluation was the best response record from the beginning to the end of treatment with anlotinib.

Statistical analysis

Statistical analysis was performed using SPSS version 25.0. Categorical variables were compared by Pearson's chi-square test or Fisher's exact test. Create a survival curve using the Kaplan–Meier method. Propensity score matching (PSM) was performed with 1:1 nearest neighbor matching (caliper 0.2) using R 4.0.3 software. P<0.05 (both sides) was considered statistically significant.

Results

Baseline characteristics of patients

A total of 160 patients were eligible for efficacy analysis. The research flow chart was shown in Figure 1. The median age of patients was 55 years (range 34-80 years) in group A and 63 years (range 29-85
years) in group B. The pathological types of group A were adenocarcinoma (71 cases, 85.5%), squamous cell carcinoma (6 cases, 7.2%) and other types (6 cases, 7.2%). The pathological types of patients in group B were adenocarcinoma (42 cases, 54.5%), squamous cell carcinoma (19 cases, 24.7%) and other types (16 cases, 20.8%). Patients in group A were all stage IV, while group B were mainly stage IV (70 patients, 90.9%), including 7 patients (9.1%) who were inoperable stage III/IV. Median prior treatment lines were 3 in group A and 2 in group B. Other baseline characteristics included PD-L1 expression level, brain metastasis, liver metastasis, Eastern Cooperative Oncology Group (ECOG) score, smoking history, history of targeted therapy, and specific treatment regimens, etc. were shown in Table 1.

Baseline characteristics of patients after matching

Comparing the baseline characteristics of patients, the two groups were not balanced in the following factors: gender (P=0.020), age (P=0.000), pathological type (P=0.000), clinical stage (P=0.015), PD-L1 expression level (P=0.019), smoking history (P=0.02), number of previous treatment lines (P=0.000), history of targeted therapy (P=0.024), therapeutic schemes (P=0.014), the difference was statistically significant (Table 1). In order to control the influence of confounding factors between the two groups, PSM was used to match the two groups in a 1:1 ratio (caliper 0.2). The matching factors were gender, age (< 60 years old, ≥ 60 years old), histological subtypes (adenocarcinoma, squamous cell carcinoma, others), clinical stage (stage IV), and the number of previous treatment lines (<3 lines, ≥3 lines). After matching, the baseline characteristics of the two groups were equalized and comparable (Table 2).

Comparison of efficacy between two groups

The optimal response of group A was partial response (PR) (n =8), stable disease (SD) (n = 51) and progression disease (PD) (n =24). The optimal response of group B was PR (n =8 cases), SD (n = 55 cases) and PD (n =14 cases). The objective response rate (ORR) and disease control rate (DCR) of the two groups were 9.6% in group A vs. 10.4% in group B (P=0.874), and 71.1% in group A vs. 80.5% in group B (P=0.165), respectively (Table 3).

The median OS was 14.6 months (95%CI 11.1-18.1) and the median PFS for the overall population was 3.8 months (95%CI 3.1-4.5). The median OS was 11.8 months (95%CI 6.7-16.9) in group A vs. 16.1 months (95%CI 12.6-19.6) in group B (P=0.121) (Figure 2). Median PFS was 3.1 months in group A (95%CI 2.3-3.9) vs. 4.7 months in group B (95%CI 3.9-5.5), P=0.009 (Figure 3).

After matching, the median OS of the two groups was 14.6 months (95%CI 10.1-19.1) in group A vs. 16.2 months (95%CI 9.2-23.2) in group B, P=0.320 (Figure 4). Median PFS was 3.5 months (95%CI 2.7-4.3) in group A vs. 4.5 months (95%CI 3.7-5.3) in group B, P=0.040 (Figure 5). The ORR and DCR of two groups were 13.0% in group A vs. 10.9% in group B (P=0.748) and 78.3% in group A vs. 82.6% in group B (P=0.599), respectively (Table 3).

Effect of previous antiangiogenic therapy on anlotinib
The effect of previous antiangiogenic treatment on anlotinib in group A was further analyzed, and Kaplan-Meier analysis showed that the different drug used previously (bevacizumab or endostar), the best response (PR, SD or PD) of the prior antiangiogenesis therapy, and PFS (≤6 months or > 6 months) of the prior antiangiogenesis therapy had no significant effect on the efficacy (PFS and OS) of patients received anlotinib (P>0.05) (Table 4).

**Safety analysis**

No life-threatening adverse events associated with anlotinib were found in the study. In group A, 6 patients were discontinued spontaneously due to intolerant adverse reactions, including 1 patient due to vaginal bleeding and fatigue, 1 patient due to hematuria, 3 patients due to skin symptoms, and 1 patient due to nausea and vomiting. In group B, 4 patients were discontinued due to intolerant adverse reactions, including 1 patient due to nausea and vomiting, 1 patient due to hand-foot syndrome, 1 patient due to acute stroke, and 1 patient due to upper gastrointestinal bleeding after diagnosis of esophageal cancer.

There was no statistical difference in the incidence of adverse events between the two groups. The most common adverse events in group A were skin symptoms (24.1%), including rash, pruritus, hand and foot syndrome, followed by hypertension (8.4%) and fatigue (6.0%). Other relatively rare adverse events of concern included vaginal bleeding (3.6%), nosebleeds (2.4%), and hematuria (1.2%). The most common adverse events in group B were skin symptoms (14.3%), hypertension (10.4%), and anorexia (10.4%), followed by diarrhea (7.8%) and fatigue (7.8%). Other relatively uncommon adverse events of concern included hemoptysis (2.6%), upper gastrointestinal bleeding (1.3%), and stroke (1.3%) (Table 5).

**Analysis of the subsequent treatment after the progression of anlotinib**

After progression of anlotinib, 57 patients (68.7%) in group A and 61 patients (79.2%) in group B received subsequent therapy. There was no statistically significant difference of subsequent line therapy between the two groups before and after matching. The most common posterior line treatments in both groups were targeted therapy, immunotherapy, and radiotherapy, while the other relatively uncommon treatments were chemotherapy and liver interventional therapy. The posterior line treatment of a few patients were unknown (Table 6).

**Discussion**

Angiogenesis plays an important role in the growth, proliferation and metastasis of tumors[28]. There are two main approaches to target tumor angiogenesis, one is the monoclonal antibody that prevents VEGF from interacting with endothelial cell surface VEGFR, and the other is the small molecule TKI that simultaneously inhibits VEGFR, PDGFR and FGFR. Bevacizumab is a recombinant human-derived IgG1 monoclonal antibody that binds to VEGF to inhibit binding to VEGFR 1-2 [29]. Bevacizumab in combination with chemotherapy was a first-line treatment for advanced NSCLC, the median PFS was about 5.9-9.2 months[4, 6, 30], and the ORR was about 35%[31]. Among the small-molecule TKIs, except nintedanib[32] and anlotinib[13, 15], most TKIs, such as sorafenib, sunitinib and apatinib, can
significantly prolong the PFS of patients, but do not significantly increase the OS benefit [28, 29, 33-36]. Anlotinib became one of the few multitarget angiogenesis inhibitors with survival benefit. In the ALTER0303 study, anlotinib as third- and further-line treatment in patients with advanced NSCLC was found to have a significant PFS extension of 4.0 months compared with placebo, a median OS extension of 3.3 months and a 32% reduction in risk of death[13]. In the ALTER1202 study, patients with limited or extended-stage SCLC received anlotinib in the third- and further-line setting, achieved PFS of 4.1 months (0.7 months in the placebo group)[37].

In this study, the median PFS of the whole population was 3.8 months and the median OS was 14.6 months, which also confirmed that in the real world, anlotinib could bring PFS and OS benefit in patients with advanced lung cancer, and the benefit seemed to be not inferior to the previously reported second-line docetaxel and immune checkpoint inhibitors [38, 39].

We found that patients who had previously received bevacizumab and endostar had a shorter PFS (3.1 months vs. 4.7 months), but the ORR, DCR, and OS were similar to those who had received the first antiangiogenesis therapy (anlotinib). The PFS of our study was similar to the PFS reported in the ALTER0303 trial, with a slightly longer OS than that of ALTER0303, which might be due to the higher subsequent-line treatment rate in our study. After reducing potential confounders between groups by PSM, it was also found that previous antiangiogenic therapy only affected PFS in patients treated with anlotinib, but may not affect OS, and the survival benefit may be due to the multi-target inhibition of anlotinib.

The incidence of adverse events recorded in both groups was low and similar to those reported in the literature[25, 40-46]. In this study, the proportion of patients rechecking ECG, thyroid function and urine routine was small. Therefore, the incidence of abnormal ECG, increased thyroid stimulating hormone (TSH) and proteinuria were lower than the actual situation and the incidence reported in previous studies. It is necessary to further strengthen the monitoring of adverse reactions during treatment.

Most patients received subsequent therapy after failure of anlotinib, and there was no difference in subsequent therapy between two groups. The most common treatment were targeted therapy and immunotherapy. With the popularity of more targeted agents and immunotherapy drugs, as well as lower toxicity compared with chemoradiotherapy, targeted therapy and immunotherapy have become the alternatives for patients with poor ECOG scores after multpline therapy, which may be one reason why the median OS in this study was slightly longer than that in ALTER0303.

**Limitations**

Results of this study was according to the experience of single-center, small sample size. The baseline characteristics of patients between the two groups were influenced by confounding factors before matching. The variety of drugs used in combination with anlotinib may affect the outcome.

**Conclusions**
Based on limited data available in this study, anlotinib may bring PFS and OS benefits to patients with advanced lung cancer. Previous antiangiogenesis treatments may affect the PFS of patients who receive anlotinib later, but it might not affect the patient's ORR and OS. The use of anlotinib in patients with advanced lung cancer after the progression of antiangiogenic therapy is worthy of subsequent prospective, large-sample clinical studies.

**Declarations**

**Consent for publication** We agree to publish the magazine.

**Availability of data and material** We have full control of all primary data and agree to allow the journal to review their data if requested.

**Authors' contributions** All authors contributed to the study conception and design. Data collection and analysis were performed by Jiaojiao Suo, Weigang Xiu and Hao Wei. The first draft of the manuscript was written by Jiaojiao Suo, Yu Sun and Yan Fu. Yan Wang: Determination of topics, essay structure and revision of manuscripts. Jiang Zhu: In charge of the whole study, perform the final revision of the manuscript. All authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

**Funding** The authors did not receive any outside funding or grants.

**Conflict of Interest** The authors declare that they have no conflict of interest.

**Ethical approval** This study was approved by Biomedical Research Ethics Committee (approval number: 2020162), West China Hospital, Sichuan University and performed in accordance with the ethical standards laid down in the 1964 declaration of Helsinki and all subsequent

**References**

1. International Agency for Research on Cancer (IARC) [EB/OL]. Available from: [https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/](https://www.iarc.fr/faq/latest-global-cancer-data-2020-qa/).
2. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2020;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001.
3. NCCN Clinical Practice Guidelines in Oncology-Non Small Cell Lung Cancer(2021 Version I)[DB/OL]. Available from: [http://www.nccn.org](http://www.nccn.org).
4. Tsai CM, Au JS, Chang GC, Cheng AC, Zhou C, Wu YL. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAiL) study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2011;6(6):1092-7. doi: 10.1097/JTO.0b013e318216687d.
5. Zhou C, Wu YL, Chen G, Liu X, Zhu Y, Lu S, et al. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.
Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2015;33(19):2197-204. doi: 10.1200/JCO.2014.59.4424.

6. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009;27(8):1227-34. doi: 10.1200/jco.2007.14.5466.

7. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2000;18(10):2095-103. doi: 10.1200/jco.2000.18.10.2095.

8. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(9):1589-97. doi: 10.1200/jco.2004.08.163.

9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in Previously Treated Non–Small-Cell Lung Cancer. New England Journal of Medicine. 2005;353(2):123-32. doi: 10.1056/NEJMoa050753.

10. Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2021;39(6):619-30. doi: 10.1200/jco.20.01055.

11. Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. Journal of hematology & oncology. 2019;12(1):47. doi: 10.1186/s13045-019-0736-3.

12. Si X, Zhang L, Wang H, Zhang X, Wang M, Han B, et al. Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer. Lung Cancer. 2018;122:32-7. doi: 10.1016/j.lungcan.2018.05.013.

13. Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018;4(11):1569-75. doi: 10.1001/jamaoncol.2018.3039.

14. Han B, Li K, Zhao Y, Li B, Cheng Y, Zhou J, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302). Br J Cancer. 2018;118(5):654-61. doi: 10.1038/bjc.2017.478.

15. Cheng Y, Wang Q, Li K, Shi J, Liu Y, Wu L, et al. Overall survival (OS) update in ALTER 1202: Anlotinib as third-line or further-line treatment in relapsed small-cell lung cancer (SCLC). Annals of Oncology. 2019;30. doi: 10.1093/annonc/mdz264.002.

16. Ruiz-Cordero R, Devine WP. Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer. Surgical pathology clinics. 2020;13(1):17-33. doi: 10.1016/j.path.2019.11.002.
17. Garcia J, Hurwitz H, Sandler A, Miles D, Coleman R, Deurloo R, et al. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer treatment reviews. 2020;86:102017.doi: 10.1016/j.ctrv.2020.102017.

18. Wang J, Sun Y, Liu Y, Yu Q, Zhang Y, Li K, et al. [Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients]. Zhongguo Fei Ai Za Zhi. 2005;8(4):283-90.doi: 10.3779/j.issn.1009-3419.2005.04.07.

19. Lin B, Song X, Yang D, Bai D, Yao Y, Lu N. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRbeta and FGFR1. Gene. 2018;654:77-86.doi: 10.1016/j.gene.2018.02.026.

20. Bennouna J, Sastre J, Arnold D, Strobl P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology. 2013;14(1):29-37.doi: 10.1016/s1470-2045(12)70477-1.

21. Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, et al. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26(7):1427-33.doi: 10.1093/annonc/mdv197.

22. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2013;381(9863):303-12.doi: 10.1016/s0140-6736(12)61900-x.

23. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2015;16(6):619-29.doi: 10.1016/s1470-2045(15)70156-7.

24. Xing P, Mu Y, Wang Y, Hao X, Zhu Y, Hu X, et al. Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. Thoracic Cancer. 2018;9(12):1716-24.doi: 10.1111/1759-7714.12886.

25. Wu D, Nie J, Dai L, Hu W, Zhang J, Chen X, et al. Salvage treatment with anlotinib for advanced non-small cell lung cancer. Thorac Cancer. 2019;10(7):1590-6.doi: 10.1111/1759-7714.13120.

26. Wang L, He Z, Yang S, Tang H, Wu Y, Li S, et al. The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial. Transl Lung Cancer Res. 2019;8(5):575-83.doi: 10.21037/tlcr.2019.09.21.

27. Wang Q, Han B, Li K, Zhang L, Shi J, Wang Z, et al. Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an
exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect. Journal of Clinical Oncology. 2018;36(15_suppl):e21182-e.doi: 10.1200/JCO.2018.36.15_suppl.e21182.

28. Qiang H, Chang Q, Xu J, Qian J, Zhang Y, Lei Y, et al. New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer. J Cancer Res Clin Oncol. 2020;146(3):631-45.doi: 10.1007/s00432-020-03129-6.

29. Hall RD, Le TM, Haggstrom DE, Gentzler RD. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015;4(5):515-23.doi: 10.3978/j.issn.2218-6751.2015.06.09.

30. Zhou CC, Bai CX, Guan ZZ, Jiang GL, Shi YK, Wang MZ, et al. Safety and efficacy of first-line bevacizumab combination therapy in Chinese population with advanced non-squamous NSCLC: data of subgroup analyses from MO19390 (SAiL) study. Clin Transl Oncol. 2014;16(5):463-8.doi: 10.1007/s12094-013-1102-5.

31. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50.doi: 10.1056/NEJMoa061884.

32. Reck M, Kaiser R, Mellemgaard A, Douillard J-Y, Orlov S, Krzakowski M, et al. Docetaxel plus nilotinib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. The Lancet Oncology. 2014;15(2):143-55.doi: 10.1016/s1470-2045(13)70586-2.

33. Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, et al. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2015;10(12):1745-53.doi: 10.1097/jto.0000000000000693.

34. Baggstrom MQ, Socinski MA, Wang XF, Gu L, Stinchcombe TE, Edelman MJ, et al. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017;12(5):843-9.doi: 10.1016/j.jtho.2017.01.022.

35. Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Current oncology reports. 2015;17(6):26.doi: 10.1007/s11912-015-0448-y.

36. Zhang N, Guo N, Tian L, Miao Z. Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials. Oncotarget. 2018;9(83):35439-47.doi: 10.18632/oncotarget.24967.

37. Cheng Y, Wang Q, Li K, Shi J, Wu L, Han B, et al. OA13.03 Anlotinib as Third-Line or Further-Line Treatment in Relapsed SCLC: A Multicentre, Randomized, Double-Blind Phase 2 Trial. Journal of Thoracic Oncology. 2018;13(10):S351-S2.doi: 10.1016/j.jtho.2018.08.308.
38. Gubens MA, Wakelee HA. Docetaxel in the treatment of non-small cell lung carcinoma: an update and analysis. Lung Cancer (Auckland, NZ). 2010;1:63-76. doi: 10.2147/lctt.s6499.

39. Lee C, Man J, Lord S, Cooper W, Links M, Gebski V, et al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA oncology. 2018;4(2):210-6. doi: 10.1001/jamaoncol.2017.4427.

40. Cheng JD, Chai LX, Zhao ZP, Hao YY, Li S. Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor. Cancer management and research. 2020;12:5641-50. doi: 10.2147/CMAR.S253366.

41. Shao L, Wang W, Song Z, Zhang Y. The efficacy and safety of anlotinib treatment for advanced lung cancer. Onco Targets Ther. 2019;12:6549-54. doi: 10.2147/OTT.S205674.

42. Zhang K, Ma X, Gao H, Wang H, Qin H, Yang S, et al. Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study. Cancer management and research. 2020;12:3409-17. doi: 10.2147/CMAR.S246000.

43. Zhong Y, Wei Q, Lu Y, Tang X, Wang Z, Chen L. Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer. Journal of thoracic disease. 2020;12(10):6016-22. doi: 10.21037/jtd-20-2855.

44. Song PF, Xu N, Li Q. Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions. Cancer Manag Res. 2020;12:11133-43. doi: 10.2147/CMAR.S275624.

45. Yang S, Zhang W, Chen Q, Guo Q. Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study. Cancer Manag Res. 2020;12:10333-40. doi: 10.2147/CMAR.S280096.

46. Wang HY, Chu JF, Zhao Y, Tang H, Wang LL, Zhou MQ, et al. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. Cancer Manag Res. 2020;12:3827-34. doi: 10.2147/CMAR.S249678.

Tables

Table 1 Baseline characteristics of Patients
| Characteristics          | Group A n=83 | Group B n=77 | P value |
|--------------------------|--------------|--------------|---------|
| Gender                   |              |              | 0.020   |
| Male                     | 41%49.4%     | 52%67.5%     |         |
| Female                   | 42%50.6%     | 25%32.5%     |         |
| Age (years)              |              |              | 0.000   |
| median (range)           | 5534-80      | 6329-85      |         |
| ≥60                      | 59%71.1%     | 33%42.9%     |         |
| ≥60                      | 24%28.9%     | 44%57.1%     |         |
| Pathology                |              |              | 0.000   |
| Adenocarcinoma           | 71%85.5%     | 42%54.5%     |         |
| Squamous cell carcinoma  | 6%7.2%       | 19%24.7%     |         |
| Others                   | 6%7.2%       | 16%20.8%     |         |
| Stage                    |              |              | 0.015   |
| IIIIB/IIIC               | 0%0%         | 7%9.1%       |         |
| IV                       | 83%100.0%    | 70%90.9%     |         |
| PD-L1                    |              |              | 0.019   |
| 0                        | 42%50.6%     | 21%27.3%     |         |
| 1-49                     | 12%14.5%     | 13%16.9%     |         |
| ≥50                      | 11%13.3%     | 13%16.9%     |         |
| NA                       | 18%21.7%     | 30%39.0%     |         |
| Brain metastases         |              |              | 0.150   |
| Yes                      | 35%42.2%     | 24%31.2%     |         |
| No                       | 48%57.8%     | 53%68.8%     |         |
| Liver metastasis         |              |              | 0.654   |
| Yes                      | 18%21.7%     | 19%24.7%     |         |
| No                       | 65%78.3%     | 58%75.3%     |         |
| ECOG                     |              |              | 0.895   |
| 0                        | 10%12.0%     | 9%11.7%      |         |
| 1                        | 37%44.6%     | 33%42.9%     |         |
Table 2 Comparison of baseline characteristics of patients after 1:1 matching of propensity score matching

| Characteristics                      | Group A n=83, % | Group B n=77, % | P value |
|--------------------------------------|-----------------|-----------------|---------|
| 2                                    |                 |                 |         |
| 3                                    | 32±38.6%        | 29±37.7%        |         |
| Smoking history                      |                 |                 | 0.02    |
| Yes                                  | 23±27.7%        | 35±45.5%        |         |
| No                                   | 60±72.3%        | 42±54.5%        |         |
| No. of Previous therapy lines        |                 |                 | 0.000   |
| median (range)                       | 3               | 2               |         |
| ≤ 3                                  | 36±43.4%        | 57±74.0%        |         |
| ≥ 3                                  | 47±56.6%        | 20±26.0%        |         |
| History of targeted therapy          |                 |                 | 0.024   |
| Yes                                  | 32±38.6%        | 17±22.1%        |         |
| No                                   | 51±61.4%        | 60±77.9%        |         |
| Previous antiangiogenic drugs        |                 |                 | -       |
| Bevacizumab                          | 73±88.0%        | 0±0%            |         |
| Endostar                             | 10±12.0%        | 0±0%            |         |
| Therapeutic schemes                  |                 |                 | 0.014   |
| Anlotinib monotherapy                | 47±56.6%        | 40±51.9%        |         |
| Chemotherapy+anlotinib               | 23±27.7%        | 11±14.3%        |         |
| Immunotherapy+anlotinib              | 6±7.2%          | 17±22.1%        |         |
| Radiotherapy+anlotinib               | 4±4.8%          | 8±10.4%         |         |
| Targeted therapy+anlotinib          | 3±3.6%          | 1±1.3%          |         |

Note: NA, not available; ECOG, Eastern Cooperative Oncology Group
| Characteristics          | Group A n=46, % | Group B n=46, % | P value |
|-------------------------|----------------|----------------|---------|
| Gender                  |                |                | 0.529   |
| Male                    | 24 52.2%       | 27 58.7%       |         |
| Female                  | 22 47.8%       | 19 41.3%       |         |
| Age (years)             |                |                | 0.833   |
| median (range)          | 57 34-80       | 57 29-82       |         |
| <60                     | 26 56.5%       | 27 58.7%       |         |
| ≥60                     | 20 43.5%       | 19 41.3%       |         |
| Pathology               |                |                | 0.778   |
| Adenocarcinoma          | 34 73.9%       | 31 67.4%       |         |
| Squamous cell carcinoma | 6 13.0%        | 7 15.2%        |         |
| Others                  | 6 13.0%        | 8 17.4%        |         |
| Stage                   |                |                | 1.000   |
| IIIB/IIIC               | 0 0%           | 0 0%           |         |
| IV                      | 46 100.0%      | 46 100.0%      |         |
| PD-L1                   |                |                | 0.239   |
| 0                       | 21 45.7%       | 16 34.8%       |         |
| 1-49                    | 8 17.4%        | 4 8.7%         |         |
| ≥50                     | 6 13.0%        | 7 15.2%        |         |
| NA                      | 11 23.9%       | 19 41.3%       |         |
| Brain metastases        |                |                | 0.832   |
| Yes                     | 19 41.3%       | 18 39.1%       |         |
| No                      | 27 58.7%       | 28 60.9%       |         |
| Liver metastasis        |                |                | 0.470   |
| Yes                     | 10 21.7%       | 13 28.3%       |         |
| No                      | 36 78.3%       | 33 71.7%       |         |
| ECOG                    |                |                | 0.393   |
| 0                       | 6 13.0%        | 7 15.2%        |         |
| 1                       | 24 52.2%       | 18 39.1%       |         |
Table 3 Comparison of the best response between the two Groups

| Characteristics                          | Group A | Group B | P value |
|-----------------------------------------|---------|---------|---------|
| 2                                       | 14%30.4% | 17%37.0% |         |
| 3                                       | 2%4.3% | 4%8.7% |         |
| Smoking history                         |         |         | 0.825   |
| Yes                                     | 31%67.4% | 30%65.2% |         |
| No                                      | 15%32.6% | 16%34.8% |         |
| No. of previous therapy lines           |         |         | 0.400   |
| ≥3                                      | 22%47.8% | 18%39.1% |         |
| History of targeted therapy             |         |         | 1.000   |
| Yes                                     | 15%32.6% | 15%32.6% |         |
| No                                      | 31%67.4% | 31%67.4% |         |
| Therapeutic schemes                     |         |         | 0.053   |
| Anlotinib monotherapy                   | 19%41.3% | 24%52.2% |         |
| Chemotherapy+anlotinib                  | 15%32.6% | 8%17.4% |         |
| Immunotherapy+anlotinib                 | 5%10.9% | 11%23.9% |         |
| Radiotherapy+anlotinib                  | 4%8.7% | 3%6.5% |         |
| Targeted therapy+anlotinib              | 3%6.5% | 0%0% |         |

Note: NA, not available; ECOG, Eastern Cooperative Oncology Group

Table 3 Comparison of the best response between the two Groups
Table 4 Analysis of the efficacy of anlotinib in Group A

|                                               | PFS months | P value | OS months | P value |
|-----------------------------------------------|------------|---------|-----------|---------|
| Previous antiangiogenic drugs                 | 0.973      | 0.249   |           |         |
| Bevacizumab (n=73)                            | 3.2 (2.3-4.1) | 11.8 (8.3-15.3) | 0.973      | 0.249   |
| Endostar (n=10)                               | 2.1 (0.0-4.9)  | 15.2 (6.1-24.3) | 0.973      | 0.249   |
| Optimal response of Previous antiangiogenic   | 0.918      | 0.859   |           |         |
| therapy                                       | PFS of previous antiangiogenic therapy | 0.592 | 0.131 |
| PR                                           | 2.7 (0.9-4.5) | 17.0 (5.6-28.4) | 0.918      | 0.859   |
| SD                                           | 3.1 (2.0-4.2) | 10.0 (4.4-15.6) | 0.918      | 0.859   |
| PD                                           | 3.8 (1.7-5.9) | 15.2 (5.2-25.2) | 0.918      | 0.859   |
| ≤6months                                      | 2.9 (1.7-4.1) | 11.1 (6.6-15.6) | 0.592      | 0.131   |
| ≥6months                                      | 3.3 (1.8-4.8) | 12.7 (3.1-22.3) | 0.592      | 0.131   |

Table 5 Adverse events with anlotinib
| Adverse events                        | Group A n=83, % | Group B n=77, % | P value |
|--------------------------------------|----------------|----------------|---------|
| **General reaction**                 |                |                |         |
| Fatigue                              | 56.0           | 67.8           | 0.659   |
| Decreased appetite                   | 44.8           | 810.4          | 0.181   |
| Weight loss                          | 11.2           | 0.0            | 1.000   |
| **Gastrointestinal reactions**       |                |                |         |
| Diarrhea                             | 22.4           | 67.8           | 0.231   |
| Oral mucositis                       | 33.6           | 33.9           | 1.000   |
| Nausea/vomiting                      | 33.6           | 35.2           | 1.000   |
| Constipation                         | 0.0            | 11.3           | 0.481   |
| Hiccup                               | 11.2           | 11.3           | 1.000   |
| **Cardiovascular symptoms**          |                |                |         |
| Hypertension                         | 78.4           | 810.4          | 0.672   |
| Premature atrial contractions        | 11.2           | 0.0            | 1.000   |
| Skin symptom                         | 2024.1         | 1114.3         | 0.117   |
| Proteinuria                          | 11.2           | 0.0            | 1.000   |
| **Hemorrhage**                       |                |                |         |
| Vaginal haemorrhage                  | 33.6           | 0.0            | 0.271   |
| Nasal hemorrhage                     | 22.4           | 0.0            | 0.498   |
| Hematuria                            | 11.2           | 0.0            | 1.000   |
| Upper gastrointestinal hemorrhage    | 0.0            | 11.3           | 0.481   |
| Hemoptysis                           | 0.0            | 22.6           | 0.230   |
| Myelosuppression                     | 33.6           | 33.9           | 1.000   |
| **Neurologic symptom**               |                |                |         |
| Dizziness                            | 11.2           | 11.3           | 1.000   |
| Insomnia                             | 11.2           | 0.0            | 1.000   |
| Stroke                               | 0.0            | 11.3           | 0.481   |
| Hypothyroidism                       | 0.0            | 11.3           | 0.481   |

Table 6 Subsequent treatment after the Progression of amlotinib theraPy
### Figures

**Figure 1**

The research flow chart
Figure 2

Comparison of OS between the two groups.
Figure 3

Comparison of PFS between the two groups.
Figure 4

Comparison of OS between the two groups after matching.

mOS: 14.6 months vs. 16.2 months (P = 0.320)
Figure 5

Comparison of PFS between the two groups after matching.